Unmet Needs in Diffuse Large B-Cell Lymphoma
Andre H. Goy, MD, and Andrew Ip, MD, offer closing remarks on unmet needs in the treatment of diffuse large B-cell lymphoma.
DLBCL: Treatment Considerations in the Second Line
Experts on diffuse large B-cell lymphoma discuss the factors that inform their treatment choices in the second line.
ZUMA-7: Axi-Cel in Patients with Relapsed/Refractory DLBCL
Experts overview the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory DLBCL, and discuss how tumor volume correlates with clinical outcomes.
L-MIND Trial: Tafasitamab plus Lenalidomide in Relapsed/Refractory DLBCL
An overview of the L-MIND trial of tafasitamab plus lenalidomide in patients with relapsed/refractory disease.
Evolving Diffuse Large B-Cell Lymphoma Treatment Landscape
Expert oncologists discuss the evolving treatment landscape for diffuse large B-cell lymphoma (DLBCL).
Future Outlook of Mantle Cell Lymphoma Treatment
Andre H. Goy, MD, and Andrew Ip, MD, offer insights on the future of mantle cell lymphoma treatment.
Second-Line Therapy Options for Relapsed/Refractory MCL
Experts on B-cell malignancies discuss second-line therapy options for patients with relapsed/refractory mantle cell lymphoma.
CAR T-Cell Therapy in Mantle Cell Lymphoma
A comprehensive overview of CAR T-cell therapy as a treatment modality for mantle cell lymphoma, including insights on the ZUMA-2 clinical trial.
BRUIN Trial: Pirtobrutinib for Patients With MCL
Expert oncologists give an overview of the BRUIN trial and discuss pirtobrutinib as a treatment for patients with mantle cell lymphoma.
Evolving Treatment Paradigms in Mantle Cell Lymphoma
Andre H. Goy, MD, and Andrew Ip, MD, discuss the ways in which treatment paradigms for mantle cell lymphoma (MCL) have recently shifted.
Next Generation of CAR-T Therapies in Lymphoma
Experts comment on the future of CAR T-cell therapy development and the use of dual CAR-T and CAR-T retreatment.
Future Perspectives on CAR-T Therapies in Lymphoma
Drs Goy, Ip, and Leslie close out their discussion with a look at the exciting developments and future of CAR T-cell therapies in lymphoma treatment.
Selecting and Sequencing Therapies to Improve Outcomes in Patients With Lymphoma
Key opinion leaders describe when to refer a patient with lymphoma and at what point treatments should be switched, and the evolution of T-cell engaging therapies.
Recent Updates on CAR-T Therapies in Chronic Lymphocytic Leukemia
Dr Lori Leslie provides an overview of key clinical trial data on the use of CAR T-cell therapy in chronic lymphocytic leukemia.
Role of CAR-T Therapies in Acute Lymphoblastic Lymphoma
Drs Goy and Leslie converse on the use of CAR T-cell therapy in acute lymphoblastic lymphoma, the first approved treatment for ALL.
CAR-T Therapies in the Follicular Lymphoma Treatment Landscape
Lori Leslie, MD, explains how CAR T-cell therapy fits into follicular lymphoma treatment sequencing, highlighting data from the ZUMA-5 trial.
Brexucabtagene Autoleucel in Mantle Cell Lymphoma
Andre Goy, MD, and Andrew Ip, MD, give an overview of the approval of CAR T-cell therapy for mantle cell lymphoma treatment.
Managing Toxicities Associated with CAR-T Therapy in LBCL
Dr Andrew Ip explains the major toxicities of CAR T-cell therapy in patients with large B-cell lymphoma and how to manage them.
CAR-T therapy in Second-Line Setting in LBCL
Lymphoma physicians from John Theurer Cancer Center comment on the use of CAR T-cell therapy in large B-cell lymphoma and the implications of clinical trial data in this setting.
Selecting the Appropriate Patients and Monitoring Responses to CAR T-Cell Therapy in LBCL
Dr Lori Leslie discusses how to assess if a patient with large B-cell lymphoma is a good candidate for CAR T-cell therapy.
Clinical Trial and Real-World Evidence Around CAR T-cell Therapy in LBCL
Andrew Ip, MD, and Lori Leslie, MD, review clinical trial and real-world data on the efficacy and survival rates of CAR T-cell therapy in large B-cell lymphoma.
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management
Here, we briefly describe the clinical efficacy of PI3K inhibitors, then discuss the mechanisms and management of the more common unusual toxicities seen with these agents.
2 Clarke Drive Cranbury, NJ 08512